Cargando…

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines

BACKGROUND: The US Food and Drug Administration (FDA) has approved several immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in other clinical studies. These inhibitors significantly increase response rates and result in the treatment of patients with advanced ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Safi, Mohammed, Ahmed, Hyat, Al-Azab, Mahmoud, Xia, Yun-long, Shan, Xiu, Al-radhi, Mohammed, Al-danakh, Abdullah, Shopit, Abdullah, Liu, Jiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020146/ https://www.ncbi.nlm.nih.gov/pubmed/33842004 http://dx.doi.org/10.1016/j.jare.2020.09.006

Ejemplares similares

Posterior Tibial Nerve Stimulation for Overactive Bladder: Mechanism, Classification, and Management Outlines
por: Al-Danakh, Abdullah, et al.
Publicado: (2022)

Aberrantly hypermethylated ARID1B is a novel biomarker and potential therapeutic target of colon adenocarcinoma
por: Baldi, Salem, et al.
Publicado: (2022)

Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation
por: Alradhi, Mohammed, et al.
Publicado: (2022)

Overall Survival in Heart Disease–Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2020)

Can bipolar transurethral enucleation of the prostate be a better alternative to the bipolar transurethral resection of the prostate?: A prospective comparative study
por: Abdulwahab Al-radhi, Mohammed, et al.
Publicado: (2021)

ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression
por: Baldi, Salem, et al.
Publicado: (2022)

Brain and heart‐specific death in cancer patients: Population‐based study
por: Safi, Mohammed, et al.
Publicado: (2021)

Laparoscopic retroperitoneal resection of the duodenal gastrointestinal stromal tumors in neurofibromatosis type 1; Case Report and literature review
por: Abdullah, Al-Danakh, et al.
Publicado: (2022)

Surgery Treatment Improved the Overall Survival Rate in Locoregional Myxoid Leiomyosarcoma than Other Myxosarcomas in the United States
por: Almoiliqy, Marwan, et al.
Publicado: (2021)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Surgery improves survival in bladder signet-ring cell carcinoma-a population-based study
por: Alradhi, Mohammed, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study
por: Al-Danakh, Abdullah, et al.
Publicado: (2022)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

PDL-1 Blockade Prevents T Cell Exhaustion, Inhibits Autophagy, and Promotes Clearance of Leishmania donovani
por: Habib, Samar, et al.
Publicado: (2018)

TL1A/TNFR2 Axis Enhances Immunoregulatory Effects of Bone Marrow Derived Mesenchymal Stem Cell by Indian Hedgehog Signaling Pathway
por: Al-Azab, Mahmoud, et al.
Publicado: (2020)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer
por: Alshaebi, Fadhl, et al.
Publicado: (2023)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021)

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
por: Patil, Sachin P., et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Aging of mesenchymal stem cell: machinery, markers, and strategies of fighting
por: Al-Azab, Mahmoud, et al.
Publicado: (2022)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy
por: Alhesa, Ahmad, et al.
Publicado: (2022)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
por: Caldwell, Charles, et al.
Publicado: (2017)

Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity
por: Garo, Lucien P., et al.
Publicado: (2019)

The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
por: Chang, Chih-Hao, et al.
Publicado: (2021)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
por: Luo, Kunpeng, et al.
Publicado: (2022)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

Anion binding properties of a hollow PdL-cage
por: Timmer, Brian J. J., et al.
Publicado: (2021)

Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis
por: Dhupkar, Pooja M, et al.
Publicado: (2015)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
por: Yin, Huanhuan, et al.
Publicado: (2020)

Survival and Pulmonary Injury After Neonatal Sepsis: PD1/PDL1's Contributions to Mouse and Human Immunopathology
por: Fallon, Eleanor A., et al.
Publicado: (2021)

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer
por: Ye, Qing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qho3r0t2tlu2mjp46eqd8vl6ig